Our data suggests that while dual PI-3K/mTOR inhibitors may improve therapeutic outcomes for a subset of ALL patients, patient selection will be important, with some patients likely to respond better to single mTOR inhibition. The gene discussed is PIK3CA; the disease is acute lymphoblastic leukemia.